<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The authors summarize their experience with the administration of small doses of <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> continuously by subcutaneous infusion in 13 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Alcysten Spofa was administered in doses of 20 mg/sq.m per day for 5-17 days in one cycle </plain></SENT>
<SENT sid="2" pm="."><plain>A total of 26 therapeutic cycles were administered </plain></SENT>
<SENT sid="3" pm="."><plain>Favourable responses were obtained in four patients, partial results were achieved in two patients; in seven instances treatment produced no response </plain></SENT>
<SENT sid="4" pm="."><plain>The authors compare also the results obtained in this group with a previous group of 11 patients treated with small doses of <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi>, which was administered intermittently, i.e. twice a day by the subcutaneous route </plain></SENT>
<SENT sid="5" pm="."><plain>Continuous administration did not produce more favourable therapeutic results, it caused however a larger number of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> and haemorrhagic complications as compared with intermittent administration </plain></SENT>
<SENT sid="6" pm="."><plain>The authors recommend administration of small doses of <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> in patients with prognostically adverse types of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> - intermittently 10 mg subcutaneously twice a day for 14-21 days </plain></SENT>
</text></document>